Related Experiment Videos
Variable response to long-term corticosteroid therapy in chronic beryllium disease.
Akshay Sood1, William S Beckett, Mark R Cullen
1Division of Pulmonary and Critical Care Medicine, Southern Illinois University School of Medicine, 701 North First Street, Room D434, PO Box 19636, Springfield, IL 62794-9636, USA. asood2@siumed.edu
Chest
|December 15, 2004
Summary
Long-term corticosteroid treatment for chronic beryllium disease (CBD) shows variable effects. Cessation of beryllium exposure may lead to significant improvements in lung function for CBD patients.
Area of Science:
- Pulmonary Medicine
- Occupational Health
Background:
- Chronic beryllium disease (CBD) shares clinical similarities with sarcoidosis.
- Corticosteroids are a common treatment for CBD, but their long-term impact is not well-documented.
Purpose of the Study:
- To investigate the effect of long-term corticosteroid therapy on the natural history of chronic beryllium disease.
- To analyze pulmonary function test trends in relation to corticosteroid treatment and beryllium exposure cessation.
Main Methods:
- Observational retrospective study of six patients with CBD.
- Mean follow-up period of 10.1 years for pulmonary function tests.
- Analysis of pulmonary function tests (FVC, Dlco) in relation to beryllium exposure and corticosteroid treatment.
Main Results:
- Two response patterns observed: no improvement with corticosteroids, or initial improvement that was not sustained.
- Cessation of beryllium exposure led to significant lung function improvement in some patients.
- Pulmonary function tests (FVC, Dlco) showed variable responses to long-term corticosteroid therapy.
Conclusions:
- Long-term corticosteroid response in CBD is variable, similar to sarcoidosis.
- Cessation of beryllium exposure is a critical factor for significant lung function improvement in CBD patients.